The company's lead product group comprises anticryptosporidial proteins which are effective when administered orally in several lab animal models and in calves. Efficacy has been shown against Cryptosporidium parvum and C. hominis. Work is ongoing to develop these both as veterinary and human pharma products.
Work in progress
• Product groups which target Staphylococcus aureus (including MRSA) and influenza viruses among other targets.
• Vaccine development for cryptosporidiosis and brucellosis.
Visit our site again soon for more specifics about our pipeline.